Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 1:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: d-ribose Clear all
Recruiting Phase 1 Interventional

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

NCT06488378
View directory record Official record
Conditions
Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
Interventions
Axatilimab, Olaparib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 25, 2026, 1:02 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

PET Imaging of PARP Activity in Cancer

NCT02469129
View directory record Official record
Conditions
Cancer
Interventions
[18F]FluorThanatrace
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 25, 2026, 1:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Study of Three Collagen Membranes: 1 Non-cross-linked and 2 Cross-linked

NCT06944639
View directory record Official record
Conditions
Bone Regeneration
Interventions
Membrane Jason MB GmbH Non-cross-linked (NCL), Membrane BioMend Extend Glutaraldehyde cross-linked, Membrane OSSIX Agile Ribose cross-linked (RCL)
Device
Lead sponsor
Andrea Ravida
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 25, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

NCT03308942
View directory record Official record
Conditions
Neoplasms
Interventions
Niraparib, Pembrolizumab, TSR-042 (Dostarlimab)
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
16
States / cities
Whittier, Alaska • Port Saint Lucie, Florida • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2023 · Synced Sep 25, 2026, 1:02 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine

NCT00516802
View directory record Official record
Conditions
Melanoma Neoplasms
Interventions
KU-0059436 (AZD2281)(PARP inhibitor), dacarbazine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2009 · Synced Sep 25, 2026, 1:02 AM EDT
Terminated Not applicable Interventional

Treating Alzheimer's and Dementia With D-ribose

NCT02260141
View directory record Official record
Conditions
Alzheimers, Dementia
Interventions
d-ribose
Dietary Supplement
Lead sponsor
Practitioners Alliance Network
Other
Eligibility
Not listed
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Kailua, Hawaii
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Sep 25, 2026, 1:02 AM EDT
Completed Phase 1 Interventional

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

NCT01469572
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
Pasireotide, Sir-sphere Radioembolization, Everolimus
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 25, 2026, 1:02 AM EDT
Completed Not applicable Interventional Results available

Comparison of Yttrium-90 Absorbed Doses Using PET/CT Versus PET/MR Imaging for Hepatic Malignancies

NCT04332419
View directory record Official record
Conditions
Hepatic Malignancies
Interventions
PET/CT, PET/MR, SIRT with Y-90
Device · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Sep 25, 2026, 1:02 AM EDT
Completed Phase 3 Interventional

Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer

NCT02106546
View directory record Official record
Conditions
Squamous Non-Small Cell Lung Cancer
Interventions
Carboplatin, Veliparib, Paclitaxel, Placebo to veliparib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
38
States / cities
Jonesboro, Arkansas • Los Angeles, California • Aurora, Colorado + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 25, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

NCT03326193
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
Niraparib, Bevacizumab
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
29
States / cities
Mobile, Alabama • Anchorage, Alaska • Mesa, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Sep 25, 2026, 1:02 AM EDT
Active, not recruiting Phase 1 Interventional

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

NCT03641755
View directory record Official record
Conditions
Breast Cancer
Interventions
Sapacitabine, Olaparib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 25, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Ovarian Cancer

NCT00494442
View directory record Official record
Conditions
Ovarian Neoplasm
Interventions
KU-0059436 (AZD2281)(PARP inhibitor)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 25, 2026, 1:02 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

NCT03368729
View directory record Official record
Conditions
Metastatic Breast Cancer, HER2 Positive Breast Carcinoma
Interventions
Niraparib, Trastuzumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Birmingham, Alabama • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 25, 2026, 1:02 AM EDT
Withdrawn Phase 2 Interventional

Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure

NCT01858480
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
D-ribose, Placebo
Drug · Other
Lead sponsor
RiboCor, Inc.
Industry
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
20
States / cities
Long Beach, California • Modesto, California • Sylmar, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 25, 2026, 1:02 AM EDT
Withdrawn Phase 2 Interventional

A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.

NCT04239014
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Olaparib, Ceralasertib, Placebo to match olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
22
States / cities
Anchorage, Alaska • La Jolla, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 25, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

NCT03414047
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Prexasertib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Tucson, Arizona • Vallejo, California • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Sep 25, 2026, 1:02 AM EDT
Recruiting Phase 1Phase 2 Interventional

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

NCT06525298
View directory record Official record
Conditions
Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency
Interventions
EIS-12656, Olaparib, Trastuzumab deruxtecan
Drug
Lead sponsor
Eisbach Bio GmbH
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 25, 2026, 1:02 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer

NCT00494234
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
2
States / cities
West Hollywood, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Sep 25, 2026, 1:02 AM EDT
Completed Not applicable Interventional

Treatment of Chronic Fatigue Syndrome and Fibromyalgia With D-ribose- a Multicenter Study

NCT01108549
View directory record Official record
Conditions
Fibromyalgia, Chronic Fatigue Syndrome
Interventions
Ribose
Dietary Supplement
Lead sponsor
Kona Research Center
Other
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 21, 2010 · Synced Sep 25, 2026, 1:02 AM EDT
Active, not recruiting Phase 1 Interventional

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

NCT03974217
View directory record Official record
Conditions
Leukemia
Interventions
Talazoparib, Decitabine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 25, 2026, 1:02 AM EDT
Active, not recruiting Phase 2 Interventional

Niraparib/TTFields in GBM

NCT04221503
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, GBM
Interventions
Niraparib, Optune, Planned surgical resection
Drug · Device · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Sep 25, 2026, 1:02 AM EDT
Not listed Early Phase 1 Interventional

Treatment of Fibromyalgia and CFS With Ribose, Ashwagandha, Rhodiola, Licorice, Schisandra and Green Tea Extract

NCT04598243
View directory record Official record
Conditions
Fibromyalgia, CFS
Interventions
Smart Energy System
Dietary Supplement
Lead sponsor
Practitioners Alliance Network
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Kailua, Hawaii
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 25, 2026, 1:02 AM EDT
Terminated Phase 2 Interventional Results available

Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer

NCT04377087
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Olaparib
Drug
Lead sponsor
Sarah E Taylor
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 25, 2026, 1:02 AM EDT
Completed Phase 1 Interventional Results available

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

NCT02723864
View directory record Official record
Conditions
Neoplasms
Interventions
Veliparib + VX-970 + Cisplatin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Bethesda, Maryland • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Sep 25, 2026, 1:02 AM EDT